In earlier work, we showed that adeno-associated virus mediated delivery of a Factor IX gene to skeletal muscle by direct intramuscular injection resulted in therapeutic levels of circulating Factor IX in mice. However, achievement of target doses in humans proved impractical because of the large number of injections required. We used a novel intravascular delivery technique to achieve successful transduction of extensive areas of skeletal muscle in a large animal with hemophilia. We provide here the first report of long-term (>3 years, with observation ongoing), robust Factor IX expression (circulating levels of 4-14%) by muscle-directed gene transfer in a large animal, resulting in essentially complete correction of the bleeding disorder in hemophilic dogs. The results of this translational study establish an experimental basis for clinical studies of this delivery method in humans with hemophilia B. These findings also have immediate relevance for gene transfer in patients with muscular dystrophy.
ABSTRACT
In earlier work, we showed that adeno-associated virus mediated delivery of a Factor IX gene to skeletal muscle by direct intramuscular injection resulted in therapeutic levels of circulating Factor IX in mice. However, achievement of target doses in humans proved impractical because of the large number of injections required. We used a novel intravascular delivery technique to achieve successful transduction of extensive areas of skeletal muscle in a large animal with hemophilia. We provide here the first report of long-term (>3 years, with observation ongoing), robust Factor IX expression (circulating levels of 4-14%) by muscle-directed gene transfer in a large animal, resulting in essentially complete correction of the bleeding disorder in hemophilic dogs. The results of this translational study establish an experimental basis for clinical studies of this delivery method in humans with hemophilia B. These findings also have immediate relevance for gene transfer in patients with muscular dystrophy.
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INTRODUCTION
In previous work, we showed that intramuscular injection of a recombinant AAV-2 vector expressing blood coagulation Factor IX (F.IX) resulted in long-term expression of F.IX, as judged by circulating F.IX levels and by immunohistochemistry of biopsied injected muscle, in mice and hemophilic dogs 1, 2 . We also showed that safety and efficacy considerations imposed an upper limit on the amount of vector that could be injected into a single site; skeletal muscle has only a limited capacity to execute essential post-translational modifications 3 , the likelihood of forming neutralizing antibodies to F.IX, an undesirable consequence, rises as the AAV dose per site is increased 4 , and vector uptake into target cells is receptor-mediated and saturable 5 . This work formed the basis for a clinical trial in which an AAV-F.IX vector was administered by direct intramuscular injection into skeletal muscle of adults with severe hemophilia B 6, 7 . The study had a dose escalation design; based on pre-clinical studies, the dose per site in the clinical trial was held to <2 x 10 12 vector genomes (vg) per injection site. The first subjects enrolled received only about ten injections, but the limitation on dose per site meant that subjects in the third and highest dose cohort required close to one hundred intramuscular injections in order to receive a dose of 2 x 10 12 vg/kg. Based on preclinical studies in mice and dogs, the dose required for efficacy was ~10 13 vg/kg, but the number of injections required for this (~500 sites) seemed prohibitive from a feasibility standpoint, and the target dose was not reached. Instead, the study was stopped after finding subtherapeutic levels of F.IX (an outcome consistent with dose-finding studies in the dog model) in two human subjects injected at a dose of 2 x 10 12 vg/kg. Three important conclusions from the human study were that: 1) intramuscular injection of 
METHODS

AAV vector construction and production
Recombinant AAV-2 vectors were produced by triple transfection as previously described, using plasmids expressing canine F.IX (cF.IX) or LacZ under the control of the CMV promoter/enhancer, a plasmid supplying adenovirus helper functions, and a third plasmid containing the AAV-2 rep and cap genes 1 .
Animal experiments
All procedures were approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania, or at the University of North Carolina at Chapel Hill.
Sedation was achieved with sodium pentothal (11 to 29 mg/kg) and anesthesia was maintained with 1-4% isoflurane.
Intravascular delivery of rAAV to the skeletal muscle of hemophilia B dogs.
Four hemophilia B dogs underwent femoral artery and vein isolation. Two overlapping tourniquets were placed transmuscularly at the level of the proximal thigh, followed by systemic heparinization at a dose of 70 U/kg injected intravenously. Heparin effect was confirmed by prolongation of activated clotting time. After tourniquets were tightened, microvascular clamps were placed to occlude the femoral vessels. The hindlimb circulation was then perfused by arterial infusion of phosphate-buffered saline (PBS).
Intra-arterial bolus injection of 1mg/kg body weight of papaverine was followed by 2.5 ml/kg of 10 mM histamine/PBS at pH 7.4. Five minutes later, AAV-cF.IX vector was infused at doses ranging from 1.7x 10 12 vg/kg to 3.9 x10 12 vg/kg in a volume of 2.5 ml/kg
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From of a solution of 10 mM histamine/PBS, at pH 7.4 followed by a 'chase' with 10ml/kg of PBS. After 15-20 minutes of the perfusion/infusion procedure, the limb circulation was flushed with 15 ml/kg of PBS. Before release of the tourniquets, animals received IV infusion of cimetidine 10 mg/kg and benedryl 2.5 mg/kg. The vessels were sutured as the cannulae were withdrawn, the clamps on the femoral vessels and tourniquets were removed, and the incision was closed with resorbable suture. Reconnection of limb vessels to systemic vasculature was routinely associated with a brief period of hypotension (1-10 min) that responded readily to volume expansion with normal saline.
Three dogs received cyclophosphamide at doses of 200-250 mg/m 2 of body surface one day prior to the day of the surgery and weekly thereafter up to 6 doses. One control animal (E60) did not receive cyclophosphamide. Pooled normal canine plasma was infused prior to the surgical procedure at doses calculated to achieve at least 30% normal cF.IX plasma levels. Muscle biopsies of the tibialis anterior of the perfused limb were taken in two dogs 2 to 3 years following vector administration.
Peripheral vein delivery of rAAV
To determine whether intravenous vector infusion by peripheral vein resulted in transgene expression, we injected a fifth hemophilia B dog at a dose of 2.9 x10 12 vg/kg rAAV-cF.IX and cyclophosphamide as described above.
Regional intravascular delivery of rAAV to the skeletal muscle of normal dogs
Two hemostatically normal dogs underwent an identical surgical procedure prior to experiments in hemophilia B dogs. One dog (6.5 kg) received infusion of rAAV-LacZ at 
Histology and Immunohistochemistry
Muscle sections were stained with hematoxylin and eosin for histology. Muscle serial cryosections (5-10 µm) were stained for cF.IX expression by immunofluorescence using 
Biodistribution and toxicity
Serial blood cell counts and biochemical analysis of serum samples for liver and kidney function tests, and muscle enzymes were performed as described before 1 .
We used a polymerase chain reaction (PCR) 9 to detect vector sequences in serum of all dogs and tissues from normal dogs (skeletal muscle of hindlimbs, liver, kidney, lung, heart, and gonads). The sensitivity of detection was 30 vector genomes per µg of DNA.
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RESULTS
Regional intravascular delivery of rAAV to the skeletal muscle results in widespread transgene expression in a large animal
We sought to determine whether a viral vector delivery technique that had been described in hamsters and rats 10 showed transduction throughout the muscle groups supplied by the injected vessel, with more extensive transduction around the stifle joint (corresponds to knee joint in humans)
than at distal sites. Systemic levels of transgene expression could not be quantified in normal dogs, since the endogenous protein and the donated gene product are identical. A biodistribution study was performed on this animal at the time of sacrifice (8 weeks after vector infusion), using a PCR assay that can detect as few as 30 copies in 1 µg DNA. Of all tissues sampled, only perfused skeletal muscle was positive for vector sequences.
Liver, lung, kidney, spleen, ovary, and contralateral muscle were all negative. The same assay showed that serum was positive for vector sequences for 5 days after vector infusion but was uniformly negative thereafter (data not shown).
Long-term correction of hemophilia B phenotype by regional intravascular delivery of rAAV to the skeletal muscle of hemophilia B dogs
To achieve a more quantitative analysis, and to determine safety and efficacy in an vg/kg (Figure 3a ). This resulted in circulating levels of cF.IX in the range of 600-800 ng/ml by ELISA, and 15% of normal human plasma levels by activity assay (Table 1) determined in several time points (ranging from 2 to 26 months) following ILP. This level of expression was sufficient to correct the activated partial thromboplastin time (aPTT) to a near normal value (Table 1, Figure 3b ). These levels have been sustained for approximately 3 years, with observation ongoing. There was no drop in F.IX level and no appearance of neutralizing or non-neutralizing antibodies to F.IX after cyclophosphamide infusions were stopped at 6 weeks post vector infusion. Since prophylaxis against spontaneous bleeding episodes does not require levels of 15%, we For (Table 1 ). This discrepancy between antigen and activity levels is typically seen in the presence of a neutralizing antibody (clinically termed an inhibitor) (Figure 4c ). The development of the inhibitor under these circumstances suggests that the transient immunosuppression cannot be omitted.
Peripheral intravenous delivery of rAAV to a hemophilia B dog results in subtherapeutic F.IX levels
In a control experiment, a hemophilic animal was infused by peripheral vein with AAV-CMV-cF.IX at a dose of 2.9 x 10 12 vg/kg, accompanied by short-term administration of cyclophosphamide and MESNA. The resulting level of F.IX was ~50 ng/ml, or approximately 1% of normal circulating levels (Figure 3a) , with a corresponding absence of positive fibers on muscle biopsy (vide infra, Figure 5g ). Thus it seems unlikely that the procedure will be successful as a simple IV infusion, at least with this AAV serotype.
Route of vector delivery to skeletal muscle does not alter patterns of rAVV-2 transduction
Muscle biopsies of the perfused limb (taken from the tibialis anterior) documented that transduction had occurred in a mosaic pattern (Figures 5a, d) 
Biodistribution and toxicity
The procedure was generally well-tolerated in both normal and hemophilic dogs, In our initial attempts to develop a clinical protocol for gene transfer in hemophilia B, we used skeletal muscle as the target tissue for an AAV vector expressing blood coagulation
Factor IX 1, 6, 7 . Compared to liver, the natural site of synthesis of F.IX, muscle is a desirable target tissue because it can be accessed in a relatively non-invasive fashion (IM Moreover, the high prevalence of hepatitis B/C in the adult hemophilia population 35, 36 (due to infection from older plasma-derived products) makes use of liver as the target tissue problematic. Therefore, we chose skeletal muscle as the target tissue in the first clinical studies of parenterally administered AAV vector. These studies established that intramuscular administration of AAV-CMV-F.IX was safe at doses up to 2 x 10 12 vg/kg in men with severe hemophilia B, and that there was long-term persistence of F.IX expression in injected muscle as judged by immunofluorescent staining of the tissue 7 .
This latter is a particularly important point, since long-term expression may be more difficult to achieve in AAV-2-mediated vector delivery to hepatocytes in humans 37 .
However, the clinical study and concurrent large animal studies documented limitations to the muscle delivery method that had not been anticipated from the initial studies in hemophilic dogs. First, it became clear in animal models of hemophilia that the risk of forming inhibitory antibodies to F.IX was higher after intramuscular delivery of AAV vector than after delivery of vector to the liver 1, 4, 12, 13, 38 . Critical determinants included the dose of vector delivered per site, and the underlying mutation in the F.IX gene, which affects the animal's immunological tolerance to the F.IX protein.
To minimize the risk of inhibitor formation in the clinical study, the dose per site was kept below a limit that had been defined in the canine hemophilia model 4 , and enrollment in the trial was limited to those with disease due to a missense mutation, a subgroup similar to the canine model, and at lower overall risk of inhibitor formation based on studies with protein infusion therapy 39, 40 . Other limiting factors included the low efficiency of skeletal muscle at executing certain critical post-translational modifications of the F.IX protein 3 , and the fact that vector uptake is receptor-mediated, which sets an upper limit to the amount of vector that can gain access to cells at a single injection site. Using the experimentally determined constraints on vector dose per site (2 x 10 12 vg/site), the procedure required an excessive number of injections merely to achieve a dose of 2 x 10 12 vg/kg, still substantially short of the target dose of 1 x 10 13 vg/kg. Without a more efficient delivery method, further dose escalation seemed impractical.
A more subtle point about vector delivery was also at play in the scale-up from mouse to dog to human. A dose of 1 x 10 13 vg/kg yielded circulating F.IX levels of 5-7% in the mice, and only 1-2% in hemophilic dogs 1,2 . The reasons for this decline in efficacy with increasing size were not entirely clear; at the time, we speculated that inter-species differences in promoter activity (i.e. a cause not related to size), or diffusion distance of the product to the circulation (more clearly related to size of organism) might account for the difference. The diffusion distance of the vector in solid tissue is fairly constant. As the radius of the muscle bundle increases with increasing size of the animal, a lower fraction of the muscle is covered per injection. Thus, direct IM injection transduces large areas of muscle in a mouse, but relatively much less in a larger animal. Put simply, two injections of AAV-lacZ turn all muscles blue in a mouse but certainly not in a dog. To achieve scale-independent dosing, one needs to take advantage of a delivery technique based on fractal rather than Euclidean geometric principles. Regional intravascular delivery, utilizing the vascular tree of the isolated limb as the delivery network, affords such a solution to the problem of scaleable delivery.
The importance of this finding for gene delivery in hemophilia is considerable; this delivery method essentially closes the 10-50-fold gap in efficacy between liver-directed and muscle-directed AAV-mediated gene transfer in large animals 1, 38 . For a disease category in which a substantial percentage (>80%) of severely affected adults have infection with hepatitis C 35, 36 , it is crucial to have a treatment strategy that does not require the liver as the target organ for transduction.
Several investigators have shown that, in mice at least, AAV serotypes 1, 6, and 7 result in much more efficient transduction of skeletal muscle [41] [42] [43] . Confirmation of these results in large animal models has recently been published 8, 44, 45 . We were able to show in the hemophilia B dog model that direct intramuscular injection of AAV-1-canine F.IX resulted initially in high level F.IX expression, but was rapidly followed by inhibitor formation that, in contrast to isolated limb perfusion with AAV-2, could not be blocked by transient immunosuppression 8 . Others have also observed the formation of antibodies to the transgene product after intramuscular injection of more potent AAV serotypes 44, 45 .
It would be of interest in their case to determine whether the transient immunosuppressive regimen that we employed could block antibody formation in their model system. All of our findings to date are consistent with the notion that high level expression of F.IX in the skeletal muscle of an animal not tolerant to the transgene product will, regardless of route of administration, trigger formation of inhibitory antibodies unless transient immunosuppression is administered 4 . Also translational studies in large animal disease models may uncover problems not appreciated in inbred strains of laboratory mice. large animals and humans. Although it will be necessary to address details of the immune response to the transgene product, and to identify an approved pharmacologic agent that can induce a vascular leak (i.e., a drug other than histamine), the studies here establish the efficacy of the strategy and thus permit us to build on the promising findings from the earlier AAV-F.IX study 7 in which vector was administered by direct IM administration.
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